## RVTY: Revvity, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($91.79)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 2, Bearish: 1)

**1. Did Revvity’s New AI Discovery Platform (RVTY) Quietly Redefine Its Innovation Moat?**
- Source: Simply Wall Street | 20251222T110841 | Somewhat-Bullish | Relevance: 100%
- Revvity, Inc. launched Signals Xynthetica, an AI Models-as-a-Service, to integrate AI into lab workflows for molecular and materials design, aiming to enhance its software revenue growth story. This platform is critical for Revvity's long-term strategy to build a high-quality, software-heavy earnings base, despite ongoing pressures in its legacy diagnostics business. The move reinforces Revvity's investment narrative focused on high-margin software capabilities.

**2. (RVTY) as a Liquidity Pulse for Institutional Tactics**
- Source: Stock Traders Daily | 20251222T205000 | Bearish | Relevance: 100%
- This article provides an institutional market analysis for Revvity Inc. (NASDAQ: RVTY), highlighting weak sentiment across all horizons and suggesting a short bias. It details an exceptional 39.6:1 risk-reward short setup and offers three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis indicating weak signals across near-term, mid-term, and long-term horizons, accompanied by support and resistance levels.

**3. Did Revvity’s New AI Discovery Platform (RVTY) Quietly Redefine Its Innovation Moat?**
- Source: Simply Wall Street | 20251222T112310 | Bullish | Relevance: 100%
- Revvity, Inc. launched Signals Xynthetica, an AI-powered platform for molecular and materials design, aiming to integrate AI directly into laboratory workflows. This move reinforces Revvity's strategy to shift towards higher-margin, software-enabled tools, offsetting pressures in legacy diagnostics and supporting recurring digital revenue. Despite the promising AI advancements, the company still faces risks from tightening reimbursement policies and pricing pressure in diagnostics, with its long-term financial health depending on a balance between AI investments and capital returns.

**4. Revvity introduces AI-augmented design platform for molecular and materials discovery**
- Source: BioSpectrum India | 20251222T074102 | Bullish | Relevance: 100%
- Revvity, Inc. has announced Signals Xynthetica™, an AI-augmented design platform for molecular and materials discovery. This platform integrates in-silico generation, predictive modeling, and experimental validation, allowing scientific teams to iteratively refine candidate molecules. Signals Xynthetica aims to bridge the gap between powerful AI models and real-world experimental data, providing a Models-as-a-Service (MaaS) offering to streamline the application and governance of predictive models in scientific research.

**5. Goldman Sachs and KeyBanc are Bullish on Danaher (DHR)**
- Source: Finviz | 20251221T210821 | Neutral | Relevance: 57%
- Goldman Sachs initiated coverage on Danaher Corporation (NYSE: DHR) with a Buy rating and a $265 price target, citing its strong bioprocessing franchise and expectations for easing equipment market overhangs. KeyBanc Capital Markets also highlighted Danaher as a top pick for 2026 in the Life Sciences Tools & Services industry, anticipating recovery and conservative core revenue growth guidance. Both firms foresee increased biopharma spending and a positive outlook for Danaher, a leading global life sciences and diagnostics innovation company.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Barclays | $115 | $105 | +10% |
| 2025-12-15 | Wells Fargo | $107 | $102 | +5% |
| 2025-12-09 | Goldman Sachs | $105 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | Wells Fargo | main | Equal-Weight |
| 2025-12-09 | Goldman Sachs | init | Neutral |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- T. Rowe Price Invest: 19.9% (-0.6%)
- Vanguard Group Inc: 11.9% (-4.0%)
- Blackrock Inc.: 8.2% (+4.4%)
- Edgepoint Investment: 7.6% (+26.3%)
- Price (T.Rowe) Assoc: 7.2% (+2.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.9% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (9.1%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.63 indicates undervaluation relative to growth. Forward P/E 18.4x stretched relative to 8% growth. Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.3B |
| Beta | 1.06 |
| 52W Range | $81.36 - $128.29 |
| Short Interest | 9.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.63 |
| Forward P/E | 18.4 |
| Current P/E | 19.8 |
| YoY Growth | 7.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -0.6% to -2.5% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.5pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). MACD histogram bearish (-0.76), momentum weakening. RSI neutral at 48. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.49% (CS: 22) | Weak |
| RSI_14 | 48.3 | Neutral |
| MACD Histogram | -0.76 | Bearish |
| vs SMA20 | 0.969x | Below |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.030x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.57
- **Stop Loss:** $91.79 (5.9% risk)
- **Target:** $103.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 207
- **Position Value:** $20,196.99
- **Portfolio %:** 20.20%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-26 (Est: $1.55)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.14 | $1.18 | +3.6% |
| 2025Q2 | $1.14 | $1.18 | +3.4% |
| 2025Q1 | $0.95 | $1.01 | +6.4% |
| 2024Q4 | $1.38 | $1.42 | +3.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*